PT  - JOURNAL ARTICLE
AU  - Azizi, Elham
AU  - Prabhakaran, Shyam
AU  - Brorson, James R.
TI  - Statin Initiation and early stroke recurrence in the POINT Trial Population
AID  - 10.1101/2024.05.07.24307030
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.07.24307030
4099  - http://medrxiv.org/content/early/2024/05/08/2024.05.07.24307030.short
4100  - http://medrxiv.org/content/early/2024/05/08/2024.05.07.24307030.full
AB  - Background and Purpose Benefits of statin therapy in reducing the long-term risk of ischemic stroke are well-established, but the immediate effects of statin therapy on early stroke recurrence after an initial ischemic event are less clear.Methods In this secondary analysis of POINT data, we evaluated the effects of statins on early stroke recurrence (within 7 days) and recurrence over 90 days. We also examined the effect of early statin initiation in the subgroup of subjects not on statins prior to the index event using logistic and proportional hazards models.Results In the POINT trial, 175 of 267 (65.5%) of ischemic stroke recurrences were early (within 7 days). Baseline statin treatment at the time of study entry was marginally associated with a decrease in the odds of early ischemic stroke recurrence in adjusted logistical regression analysis (OR 0.70, 95% CI 0.50-0.99, p=0.04), but with a non-significant effect in adjusted Cox proportional hazard analysis (HR=0.72, 95% CI 0.52–1.01, p=0.05). In the subset of subjects not taking statin medications at baseline, initiation of statin treatment had no significant effect on the rate of early stroke recurrence (adjusted HR 0.80, 95% CI 0.54–1.20, p=0.22).Conclusion In the POINT trial population, prior treatment with statin was weakly associated with decreased risk of early recurrence of stroke. However initiating statin treatment had no detectable effect in reducing risk of early stroke recurrence. The POINT trial provides no evidence for an immediate protective effect of statins against stroke recurrence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The POINT trial dataset was provided by the National Institute of Neurological Disease and Stroke. The shared datasets included 4,881 subjects from the POINT trial. The present study was submitted to the University of Chicago Institutional Review Board and was determined to be exempt from further review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript